<DOC>
	<DOCNO>NCT02581696</DOCNO>
	<brief_summary>An open-label , multiple-dose , single-arm , phase 1 study evaluate drug-drug interaction safety Lafutidine Irsogladine maleate healthy adult volunteer</brief_summary>
	<brief_title>The Drug-drug Interaction Safety Lafutidine Irsogladine Maleate Healthy Adult Volunteers</brief_title>
	<detailed_description>A phase 1 study evaluate drug-drug interaction safety Lafutidine Irsogladine maleate healthy adult volunteer . Subjects judge appropriate study screen 28days first administration . Subjects administrate Lafutidine bid period I . After wash-out period , administrate Irsogladine maleate qd Period II . After , coadministration Lafutidine bid Irsogladine maleate qd .</detailed_description>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Lafutidine</mesh_term>
	<mesh_term>Irsogladine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>1 . Healthy subject age 19 50 screen 2 . Male subject whose weight great 55kg Female subject whose weight great 50kg within ±20 % range ideal body weight . Ideal body weight ( kg ) = ( Height ( cm ) 100 ) * 0.9 3 . For female subject must show negative urine pregnancy test also must meet one list criterion : A menopausal woman ( Menstruation stop least 2 year ago ) Take sterilization operation ( Hysterectomy , Ovariotomy , Tubal ligation , operation ) Male partner sterile prior female subject 's entry study sole sexual partner female subject . Before 3 month screen 1month end drug administration , subject must meet contraception requirement . For avoid drugdrug interaction , subject must use contraceptive drug must choose abstinence use physical block . 4 . A sexually active male subject must use accepted method contraception course clinical study must donate sperm month finish drug administration . ( If male subject oneself female partner sterility , apply . ) 5 . Subjects understand clinical study completely , agree participate sign write consent form conduct precaution 1 . Subjects liver system disorder , kidney disorder , digestive system disorder , cardiovascular disorder , respiratory disorder , endocrine disorder , neurological disorder hematological disorder , psychiatric disorder , history malignancy , disorder 2 . Subjects history gastrointestinal system disorder influence drug absorption ( i.e , Crohn 's disease , ulcer ) surgery ( except simple typhlectomy hernia repair surgery ) 3 . Subjects history hypersensitivity additional ingredient clinically significant hypersensitivity lafutidine Irsogladine drug . 4 . Subjects judge inappropriate physical examination . ( Disease history , physical examine , vital sign , EKG examine , laboratory examine ) . 5 . Galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption hereditary disorder . 6 . Subjects sit 5minutes break , Systolic blood pressure ≥ 140 mmHg Diastolic blood pressure ≤ 90 mmHg , Systolic blood pressure ≥ 90 mmHg Diastolic blood pressure ≤ 60 mmHg vital sign 7 . Subjects history drug abuse positive drug abuse urinalysis test screen . 8 . Subjects pregnancy fee breast milk . 9 . Subjects participate another clinical study study drug administration Subjects blood donation within two month component blood donation within one month study drug administration 10 . Subjects drunken beverage caffeinecontaining alcohol smoking prohibition period 11 . Subjects judge inappropriate study investigator accord reason include clinical lab test result</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>